Growing Onglyza Cases May Prove to be a Burden for the Manufacturers
Growing Onglyza Cases May Prove to be a Burden for the Manufacturers
Introduction
A product liability lawsuit was filed in the U.S. District Court for the Southern District of Ohio by the widow of an Ohio man, who claims the use of Onglyza was the reason for the congestive heart failure suffered by her husband before his death.
Onglyza cases are centralized as a part of MDL No. 2809, which is witnessing a steady rise in the number of lawsuits as expected since its establishment in February, in the U.S. District Court for the Eastern District of Kentucky under U.S. District Judge Karen K. Caldwell.
Bristol-Myers Squibb and AstraZeneca are the defendants named in the Onglyza litigation over its alleged link to congestive heart failure and other side effects. Plaintiffs hold them responsible for not providing adequate cardiovascular injury warnings despite having the knowledge.
Comments
Latest News
Attorneys Seek Reconsideration of Talc MDL Daubert Ruling
Categories: General
Plaintiffs’ attorneys are urging the U.S. District Judge overseeing the talcum powder lawsuit MDL to reconsider a recent decision for a second round…
Philips resolves DreamStation suits for $1.1B
Categories: Settlements
Dutch medical technology company Philips has finalized a $1.1 billion settlement in the United States to address lawsuits concerning faulty…
FDA OKs Generic OTC Naloxone Spray Approved by FDA
Categories: FDA Related
The FDA has granted approval for Amneal Pharmaceuticals to release a generic 4 mg naloxone hydrochloride nasal spray for over-the-counter (OTC) use, an announcement made in a press release.
…